InMed Pharmaceuticals, Inc. engages in the provision of biopharmaceutical research. It operates through the InMed Pharma and BayMedica segments. The InMed Pharma segment is organized around the research and development of small molecule pharmaceuticals drug candidates. The BayMedica segment focuses on the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. It is also involved in cannabinoid-based therapies and a biosynthesis system for the manufacturing of pharmaceutical-grade cannabinoids. The company was founded by Christopher Bogart, Sazzad Hossain, Hyder A. Khoja, and Craig D. Schneider on May 19, 1981 and is headquartered in Vancouver, Canada.
No Data
No Data